Company
GentiBio
GentiBio is a clinical-stage company developing engineered Treg therapies to cure Type 1 diabetes (T1D) and other autoimmune or acute inflammatory diseases
Also known as GentiBio, Inc.
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Legal name
- GentiBio, Inc.
- gentibio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
GentiBio is a clinical-stage company developing engineered Treg therapies to cure Type 1 diabetes (T1D) and other autoimmune or acute inflammatory diseases
Funding snapshot
- Total raised
- $177MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $157M2021-08-11
Funding rounds
- Series A
- $157M2021-08-11, Company stated
- Seed
- $20M2020-08-05, Company stated
About the company
- Status notes
- GentiBio is a clinical-stage company developing engineered Treg therapies to cure Type 1 diabetes (T1D) and other autoimmune or acute inflammatory diseases
Products
- Other
- GNTI-122
Loading relationship preview